We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-18.55%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.33B
AUM Growth
-$894M
Cap. Flow
-$130M
Cap. Flow %
-5.55%
Top 10 Hldgs %
69.04%
Holding
126
New
9
Increased
16
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
NMRA icon
Neumora Therapeutics
NMRA
+$35M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
SLRN
ACELYRIN
SLRN
+$13.8M
4
IMGN
Immunogen Inc
IMGN
+$12.4M
5
SGMT icon
Sagimet Biosciences
SGMT
+$12.3M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$41.1M
2
SAGE
Sage Therapeutics
SAGE
+$23.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$15.2M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.42%
2 Consumer Discretionary 42.85%
3 Technology 0.61%
4 Communication Services 0.19%
5 Real Estate 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
101
Pliant Therapeutics
PLRX
$65M
$26K ﹤0.01%
1,490
– –
SNTI icon
102
Senti Biosciences Holdings
SNTI
$10.8M
$23K ﹤0.01%
5,556
– –
INKT icon
103
MiNK Therapeutics
INKT
$51.7M
$2K ﹤0.01%
192
-22,630
-99% -$368K
ALXO icon
104
ALX Oncology
ALXO
$262M
– –
-500,000
Closed -$3.75M
BMRN icon
105
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-5,028
Closed -$436K
CFG icon
106
Citizens Financial Group
CFG
$30.1B
– –
-10,000
Closed -$261K
CGEM icon
107
Cullinan Oncology
CGEM
$1.06B
– –
-250,000
Closed -$2.69M
CRVS icon
108
Corvus Pharmaceuticals
CRVS
$1.1B
– –
-500,000
Closed -$1.15M
DHR icon
109
Danaher
DHR
$138B
– –
-53,580
Closed -$11.4M
KRYS icon
110
Krystal Biotech
KRYS
$10.7B
– –
-349,669
Closed -$41.1M
LCID icon
111
Lucid Motors
LCID
$3.11B
– –
-49,000
Closed -$3.38M
MLTX icon
112
MoonLake Immunotherapeutics
MLTX
$1.56B
– –
-400,000
Closed -$20.4M
MRSN
113
DELISTED
Mersana Therapeutics
MRSN
– –
-121,182
Closed -$9.97M
PTGX icon
114
Protagonist Therapeutics
PTGX
$8.55B
– –
-500,000
Closed -$13.8M
RLAY icon
115
Relay Therapeutics
RLAY
$4B
– –
-1,213,725
Closed -$15.2M
SAGE
116
DELISTED
Sage Therapeutics
SAGE
– –
-500,000
Closed -$23.5M
SANA icon
117
Sana Biotechnology
SANA
$882M
– –
-400,000
Closed -$2.38M
STOK icon
118
Stoke Therapeutics
STOK
$1.84B
– –
-250,000
Closed -$2.66M
UTHR icon
119
United Therapeutics
UTHR
$26.1B
– –
-2,971
Closed -$656K
XBI icon
120
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-1,000,000
Closed -$83.2M
PFTA
121
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
– –
-380,000
Closed -$3.94M
STER
122
DELISTED
Sterling Check Corp. Common Stock
STER
– –
-25,000
Closed -$307K
MORF
123
CALL
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-100,000
Closed -$5.73M
KNTE
124
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-125,000
Closed -$379K
AMAM
125
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-702,291
Closed -$11.6M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2023 Portfolio in Review

As of Q3 2023, Artal Group held 126 positions worth $2.33B, down 28% from $3.23B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group withdrew a net $130M in Q3 2023, closing 23 positions and reducing 12 holdings. Its most notable exit was Krystal Biotech, an estimated $41.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 55% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Neumora Therapeutics worth $39.5M.

  • Artal Group's largest Q3 2023 buy was Neumora Therapeutics: 2,802,702 shares worth $39.5M.
  • Artal Group added most to Apellis Pharmaceuticals in Q3 2023, an estimated $27M increase.
  • Artal Group's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $8.06M.
  • Artal Group fully exited Krystal Biotech in Q3 2023, selling an estimated $41.1M.
  • Artal Group's ten largest holdings make up 69% of its $2.33B portfolio in Q3 2023.
  • Artal Group opened 9 new positions and closed 23 in Q3 2023.
  • Artal Group's portfolio value fell 28% quarter-over-quarter to $2.33B.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.